gdc
FDA Approvals, News & UpdatesMultiple Myeloma

FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma

Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
April 2021 Vol 7 No 2

In February 2021, the FDA approved Pepaxto (melphalan flufenamide; from Oncopeptides AB), for the treatment (in combination with dexamethasone) of adults with relapsed or refractory multiple myeloma who had received 4 or more lines of therapy and whose disease has not responded to 3 types of drugs, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Pepaxto is the first peptide–drug conjugate approved for multiple myeloma.

“Research has shown melphalan flufenamide to be a novel and innovative therapeutic option, which is active in refractory disease and has manageable toxicity, with the convenience of being administered by infusion once a month,” said Paul G. Richardson, MD, Director of Clinical Research at the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. “Based on our findings, melphalan flufenamide is an important addition to the treatment armamentarium, with the potential to meaningfully improve outcomes in an area of important unmet medical need.”

This approval was based on results for 97 patients with relapsed or refractory multiple myeloma who previously received 4 or more therapies. The patients received intravenous Pepaxto on day 1 and oral dexamethasone on days 1, 8, 15, and 22 of every 28-day cycle, until disease progression or until unacceptable side effects.

The overall response rate was 23.7% and the average duration of response was 4.2 months.

The most common side effects with melphalan flufenamide were fatigue, nausea, diarrhea, fever, and respiratory tract infection.

Share this:

Recommended For You
FDA Approvals, News & UpdatesLeukemiaLymphoma
FDA Approved Rylaze as Part of a Treatment Regimen for Young Patients with Leukemia or Lymphoma
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection.
FDA Approvals, News & UpdatesMultiple Myeloma
Darzalex Faspro Receives New FDA Indication, in Combination with Pomalyst and Dexamethasone, for the Treatment of Patients with Multiple Myeloma
In July 2021, the FDA approved a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj), for use in combination with Pomalyst (pomalidomide) and dexamethasone, for adults with multiple myeloma who have received at least 1 previous line of therapy.
Last modified: April 28, 2021

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest